1up Formulary API needs plan-and-drug effective snapshots

Separate the public catalogue from a member's claim

The direct answer is to preserve a plan-and-drug snapshot with its scope and effective time before displaying a formulary response as useful coverage guidance. 1upHealth describes its Formulary API as public-facing and without authorization. That is appropriate to a discoverable plan catalogue; it does not mean the endpoint knows an individual's active enrollment, deductible, benefit phase, network pharmacy, prior authorization decision, quantity limit exception, claim adjudication, or final price. A member-facing application should label what its public result can and cannot answer.

Identify payer, line of business, plan identifier, contract and benefit year, geographic scope, drug identifier and terminology version, strength, form and route, tier, coverage status, utilization-management conditions, covered alternatives, cost-sharing field and its assumptions, source-feed version, publish time, effective-from and effective-to dates, and response timestamp. A drug name match is not enough when brand, generic, package, route or dosage differ. If a field is unknown or varies by plan and member state, expose that uncertainty rather than presenting a generic catalogue value as a patient-specific quote.

Reconcile ingestion and time boundaries

The linked 1up product page says source formulary data is ingested, validated, mapped to Da Vinci US Drug Formulary resources, published, and synchronized on an ongoing basis. Acceptance evidence should connect received source files or API messages to validated mappings, rejected records, duplicate and superseding changes, FHIR resource identifiers, release version, application cache, and public response. Record the source change effective date separately from the date the feed arrived, when mapping succeeded, when the published API changed, and when an app last refreshed it.

Test a mid-year tier change, a plan switch, a deleted restriction, a new strength, a delayed inbound feed, and a mobile client caching an obsolete response. Reproduce exactly which value was visible at an earlier decision and whether the correction was later released. A usage dashboard that counts requests cannot establish correctness, complete payer coverage, or actual treatment decisions. Required update periods and legal applicability need confirmation against the current official rule and the payer's precise line of business; provider marketing is not a compliance opinion.

Show the restriction and handoff clearly

For each displayed option distinguish listed coverage, tier, step therapy, quantity limits, prior authorization requirement, alternatives, expected cost information, and the point at which a benefit or pharmacy transaction must confirm the result. Links to clinical decision support or electronic prior authorization should retain the selected plan and drug version but not quietly convert a public formulary look-up into a completed authorization. A switch to a member-specific workflow needs separate identity, consent, access, request and decision receipts appropriate to that purpose.

Evaluate one medication across two plans and two forms: one alternative is listed but unavailable at the chosen pharmacy, another requires an exception, and one public cost field varies by benefit phase. Verify that the consuming app does not collapse these into 'covered and affordable'. Keep the disclaimer proximate to the result, supply the governing snapshot and refresh status, and route uncertain coverage to an appropriate benefits confirmation without claiming that a public endpoint adjudicates the claim.

Evidence boundary and distinct interoperability intent

1upHealth's registered website supports attribution of its modular payer platform and Formulary offer. Its linked official product page supports the specific statements about public FHIR R4 access, source mapping, drug tiers and restrictions, alternatives, cost information, and ongoing publication. Neither page proves a buyer's feed quality, effective plan coverage, current individual benefits, reimbursement, CMS compliance, prior authorization decision or clinical outcome. Those remain payer, pharmacy, implementation and regulated-program determinations.

This is not the previously published medication-history-versus-active-medication-list distinction, CMS API enrollment/reconfiguration checklist, Moxe request-to-use lineage, or Azure de-identification method. This article asks whether a publicly exchanged drug catalogue record is displayed with the correct plan, medication and effective-time context before anyone interprets it as a coverage answer.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

Health Interoperability Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.